Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.2 USD | -0.31% | +7.38% | -22.80% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 25.86M | Capitalization | 82.19M |
---|---|---|---|---|---|
Net income 2024 * | -69M | Net income 2025 * | -69M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 3.18 x |
P/E ratio 2024 * |
-1.43
x | P/E ratio 2025 * |
-2.15
x | Employees | 54 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.9% |
Latest transcript on Leap Therapeutics, Inc.
1 day | -0.31% | ||
1 week | +7.38% | ||
Current month | +20.30% | ||
1 month | +33.33% | ||
3 months | +12.28% | ||
6 months | +119.18% | ||
Current year | -22.80% |
Managers | Title | Age | Since |
---|---|---|---|
Doug Onsi
CEO | Chief Executive Officer | 55 | 10-12-31 |
Chris Mirabelli
CHM | Chairman | 69 | 10-12-31 |
Jason Baum
CTO | Chief Tech/Sci/R&D Officer | 45 | 20-08-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph Loscalzo
BRD | Director/Board Member | 72 | 15-12-31 |
Nissim Mashiach
BRD | Director/Board Member | 63 | 16-12-31 |
Chris Mirabelli
CHM | Chairman | 69 | 10-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 3.2 | -0.31% | 89,131 |
24-04-22 | 3.21 | +14.64% | 328,700 |
24-04-19 | 2.8 | -5.41% | 213,807 |
24-04-18 | 2.96 | -1.33% | 101,762 |
24-04-17 | 3 | +0.67% | 146,417 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.80% | 82.19M | |
-0.49% | 103B | |
+3.31% | 96.73B | |
+1.66% | 21.31B | |
-16.16% | 21.21B | |
-6.82% | 18.79B | |
-41.41% | 16.37B | |
-22.87% | 13.68B | |
+6.32% | 13.44B | |
+21.46% | 10.98B |
- Stock Market
- Equities
- LPTX Stock